- Home
- /
- Treatment
- /
- Page 17
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
| Country | Product | Indication | Sponsor | Date |
|---|---|---|---|---|
|
Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing theCOL7A1gene | Dystrophic epidermolysis bullosa | Abeona Therapeutics Europe SL | February 27, 2017 |
|
Asciminib | Chronic myeloid leukemia | Novartis Pharmaceuticals Corporation;One Health Plaza;East Hanover, New Jersey, 07936 | February 27, 2017 |
|
Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 | Myelodysplastic syndromes | Opsona Therapeutics Limited | February 27, 2017 |
|
Recombinant human histidyl-tRNA synthetase | Limb-girdle muscular dystrophy | aTyr Pharma;3545 John Hopkins Court, Suite 250;San Diego, California, 92121 | February 23, 2017 |
|
6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2’H-spiro[cyclohexane-1,3′-imidazo[1,5a]pyridine]-1′,5′-dione hydrochloride | Diffuse Large B-cell Lymphoma | eFFECTOR Therapeutics;11180 Roselle Street, Suite A;San Diego, California, 92121 | February 23, 2017 |
|
Ustekinumab | Ulcerative colitis | Janssen Biotech, Inc.;1400 McKean Road;Spring House, Pennsylvania, 19477 | February 22, 2017 |
|
Abatacept | Giant cell arteritis | Bristol-Myers Squibb Research & Development;Marketed Products Development - Regulatory Strategy, P.O. Box 5326;Princeton, New Jersey, 08543 | February 22, 2017 |
|
Abatacept | Idiopathic inflammatory myopathy (IIM) | Bristol-Myers Squibb Research & Development;Marketed Products Development - Regulatory Strategy, P.O. Box 5326;Princeton, New Jersey, 08543 | February 22, 2017 |
|
Sofosbuvir/velpatasvir | Pediatric chronic hepatitis C virus (HCV) infection | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 | February 22, 2017 |
|
5-aza-2′-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one | Thalassemia | EpiDestiny Inc.;7536 Royal Portrush Drive;Solon, Ohio, 44139 | February 16, 2017 |
|
EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody | Glioblastoma | EnGeneIC Ltd;25 Sirius Road, Building 2;Lane Cove West | February 14, 2017 |
|
Nelfinavir | Multiple myeloma | Swiss Group for Clinical Cancer Research (SAKK);Effingerstrasse 33;Bern | February 14, 2017 |
|
Glucopyranosyl lipid A stable emulsion | Follicular lymphoma | Immune Design Corp.;1616 Eastlake Ave. E, Suite 310;Seattle, Washington, 98102 | February 14, 2017 |
|
Dextromethorphan hydrobromide/quinidine sulfate | Amyotrophic lateral sclerosis | Avanir Pharmaceuticals;30 Enterprise, Suite 400;Aliso Viejo, California, 92656 | February 14, 2017 |
|
Melatonin | Short bowel syndrome | Therapicon SrL;21 Via Malachia Marchesi de Taddei;Milano | February 14, 2017 |
|
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate | Diffuse Large B-cell Lymphoma | Millennium Pharmaceuticals, Inc.;40 Landsdowne Street;Cambridge, Massachusetts, 02139 | February 14, 2017 |
|
Atezolizumab | Metastatic Melanoma | Genentech, Inc.;1 DNA Way, MS 35-5E;South San Francisco, California, 94080 | February 13, 2017 |
|
Atezolizumab | Metastatic Melanoma | Genentech, Inc.;1 DNA Way, MS 35-5E;South San Francisco, California, 94080 | February 13, 2017 |
|
Sirolimus | Tuberous sclerosis | Aucta Pharmaceuticals, LLC;675 US Highway One;North Brunswick, New Jersey, 08902 | February 13, 2017 |
|
(3’R,4’S,5’R)-N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6”-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3”-indole]-5′-carboxamide mono(4-methylbenzenesulfonate) monohydrate | Liposarcoma | Daiichi Sankyo, Inc.;399 Thornall Street;Edison, New Jersey, 08837 | February 13, 2017 |
|
Copanlisib | Nodal marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 |
|
Copanlisib | Splenic marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 |
|
7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL | Mantle cell lymphoma | Oncoceutics, Inc.;3624 Market Street, Suite 5E;Philadelphia, Pennsylvania, 19104 | February 7, 2017 |
|
Copanlisib | Extranodal marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 |
|
N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt | Acute myeloid leukemia | Imago BioSciences, Inc.;2729 Debbie Court;San Carlos, California, 94070 | February 7, 2017 |
